Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K T Flaherty

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
The British Journal of Dermatology|July 12, 2020
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expectX Bai, K T Flaherty
The British Journal of Dermatology|January 22, 2014
Major therapeutic developments and current challenges in advanced melanomaR J Sullivan, K T Flaherty
British Journal of Cancer|January 22, 2009
Integrating BRAF/MEK inhibitors into combination therapy for melanomaK S M Smalley, K T Flaherty
Current Opinion in Oncology|October 24, 2001
Antisense therapeutics: lessons from early clinical trialsK T Flaherty, J P Stevenson, P J O'Dwyer
Clinical Radiology|September 8, 2020
Image-guided biopsy in the age of personalised medicine: strategies for success and safetyA O'Shea, A L Tam, A Kilcoyne, et al.
Chest|September 22, 1998
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung diseaseE L Greidinger, K T Flaherty, B White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
Cutaneous effects of BRAF inhibitor therapy: a case seriesP L Mattei, M B Alora-Palli, S Kraft, et al.
British Journal of Cancer|January 25, 2007
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levelsK S M Smalley, R Contractor, N K Haass, et al.
British Journal of Cancer|June 10, 2010
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyK H T Paraiso, I V Fedorenko, L P Cantini, et al.
Oncogene|September 17, 2008
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsK S M Smalley, M Xiao, J Villanueva, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The British Journal of Dermatology|July 12, 2020
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expectX Bai, K T Flaherty
The British Journal of Dermatology|January 22, 2014
Major therapeutic developments and current challenges in advanced melanomaR J Sullivan, K T Flaherty
British Journal of Cancer|January 22, 2009
Integrating BRAF/MEK inhibitors into combination therapy for melanomaK S M Smalley, K T Flaherty
Current Opinion in Oncology|October 24, 2001
Antisense therapeutics: lessons from early clinical trialsK T Flaherty, J P Stevenson, P J O'Dwyer
Clinical Radiology|September 8, 2020
Image-guided biopsy in the age of personalised medicine: strategies for success and safetyA O'Shea, A L Tam, A Kilcoyne, et al.
Chest|September 22, 1998
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung diseaseE L Greidinger, K T Flaherty, B White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2012
Cutaneous effects of BRAF inhibitor therapy: a case seriesP L Mattei, M B Alora-Palli, S Kraft, et al.
British Journal of Cancer|January 25, 2007
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levelsK S M Smalley, R Contractor, N K Haass, et al.
British Journal of Cancer|June 10, 2010
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyK H T Paraiso, I V Fedorenko, L P Cantini, et al.
Oncogene|September 17, 2008
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsK S M Smalley, M Xiao, J Villanueva, et al.
Pageof 2